FDA AdComm to Review Acadia’s Parkinson’s Disease Candidate

The FDA’s Psychopharmacologic Drugs Advisory Committee will convene March 29 to review Acadia Pharmaceuticals’ Nuplazid for the treatment of psychosis associated with Parkinson’s disease.

Nuplazid — which received priority review status for the indication — has a PDUFA date of May 1.